SCLXW Scilex Holding Co

BULLISH Impact: 8/10 8-K
Horizon months Filed May 5, 2026 Processed 1mo ago SEC 0001193125-26-205839
8-K material event: Items 1.01
Latest settled — T+20d
SCLXW ▲ 0.00% at T+20d
LONG call ✗ call lost 0.00% · α vs SPY -4.95% · entry $0.1360 → $0.1360
Next anchor: T+60d in 7w
Currently $0.1360 · +0.00% from $0.1360 entry
Entry anchored
May 1, 11:16 AM ET
via Databento tick
T+1d
0.00%
call 0.00% · α -1.38%
$0.1360
settled 5w ago
T+5d
0.00%
call 0.00% · α -1.98%
$0.1360
settled 29d ago
T+20d
0.00%
call 0.00% · α -4.95%
$0.1360
settled 7d ago
T+60d
call — · α —
in 7w

Price Chart

Loading chart...

Executive Summary

Scilex's indirect subsidiary ACEA Therapeutics agreed to sell 100% of ACEA Pharma to Phoenix Asia Holdings in exchange for 100 million newly-issued Phoenix shares valued at $1 billion, after which ACEA Thera will own ~82% of the renamed combined company. This reverse merger effectively monetizes Scilex's stake in ACEA Pharma at a substantial valuation relative to Scilex's current market cap.

Key Financial Metrics

Deal Value
$1.0B

Actionable Insight

Monitor for Nasdaq and regulatory approvals, which are conditions to close. If completed, Scilex will effectively control a newly public biotech entity, potentially re-rating its own valuation. Watch for any material adverse changes or deal termination risks.

Key Facts

  • Deal value agreed at $1,000,000,000 for 100,000,000 Phoenix shares at $10.00 each.
  • Upon closing, ACEA Thera (Scilex subsidiary) will own approximately 82% of the combined entity.
  • Phoenix Asia Holdings (PHOE) will be renamed ACEA Pharma, Inc. and continue trading on Nasdaq.
  • Closing expected in Q2 2026 subject to regulatory, Nasdaq, and customary conditions.

Financial Impact

The $1 billion deal valuation represents a massive multiple of Scilex's <$2M warrant market cap, potentially unlocking significant value for Scilex shareholders.

stake valueequity ownership

Risk Factors

  • Deal may fail to close due to regulatory or stock exchange issues.
  • No financials of ACEA Pharma disclosed; valuation may not be realized.
  • Scilex warrants (SCLXW) may see price volatility based on deal progress.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-205839
Document: sclx-ex99_1.htm0001193125-26-205839
Document: 0001193125-26-205839-index-headers.html0001193125-26-205839
Document: 0001193125-26-205839-index.html0001193125-26-205839
Document: 0001193125-26-205839.txt0001193125-26-205839
5 reports for SCLXW
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for SCLXW — sortable, filterable
Type Now
Jun 2, 2026
7d ago
S-3
BEARISH ★ 6/10
$0.1360 $0.1360· 0.00%▲ +0.40%$0.1360 (−0.00%)
May 26, 2026
15d ago
EFFECT
BEARISH ★ 6/10
$0.1360 $0.1360· 0.00%▲ +0.01%$0.1360 (−0.00%)
May 5, 2026
5w ago
8-K
BULLISH ★ 8/10
$0.1360 $0.1360· 0.00%▼ −1.38%$0.1360 (+0.00%)
Apr 28, 2026
6w ago
8-K
MIXED ★ 6/10
$0.1360 $0.1360· 0.00%▼ −1.02%$0.1360 (+0.00%)
Apr 16, 2026
7w ago
S-3
NEUTRAL ★ 4/10
$0.1360 $0.1360· 0.00%▲ +0.19%$0.1360 (+0.00%)
Showing 5 of 5

US Market Status

Market Closed — Opens in 6h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access